Alex van Belkum Selected Research

Ketoconazole (Nizoral)

4/2011	In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.
6/2010	Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.
7/2007	Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole.
3/2007	In vitro susceptibility of Madurella mycetomatis, prime agent of Madura foot, to tea tree oil and artemisinin.
4/2005	Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alex van Belkum Research Topics

Disease

29	Infections 01/2021 - 01/2002
11	Mycetoma 05/2016 - 03/2002
9	Guillain-Barre Syndrome 01/2012 - 12/2004
6	Bacteremia 01/2020 - 09/2003
5	Diarrhea 09/2019 - 03/2002
4	Communicable Diseases (Infectious Diseases) 07/2021 - 02/2005
4	Septic Shock (Toxic Shock Syndrome) 01/2020 - 07/2005
3	Gastroenteritis 01/2020 - 09/2012
3	Burns 01/2017 - 02/2004
3	Enteritis 10/2009 - 10/2007
2	Cystic Fibrosis (Mucoviscidosis) 11/2021 - 01/2021
2	Staphylococcal Infections 01/2020 - 02/2015
2	Cross Infection (Nosocomial Infection) 01/2020 - 01/2010
2	Wounds and Injuries (Trauma) 01/2017 - 02/2004
2	Otitis Media 06/2012 - 08/2005
2	Polyneuropathies (Polyneuropathy) 03/2008 - 12/2004
1	Leptospirosis 12/2019
1	Urinary Tract Infections (Urinary Tract Infection) 07/2019
1	Bacillary Dysentery (Shigellosis) 01/2019
1	Legionnaires' Disease (Legionnaire's Disease) 01/2017
1	Neglected Diseases 05/2016
1	Pulmonary Tuberculosis 01/2016
1	Asymptomatic Infections 02/2015
1	Epidermolysis Bullosa 02/2015
1	Tuberculosis (Tuberculoses) 03/2013
1	Disease Progression 01/2013
1	Otitis Media with Effusion 06/2012
1	Fever (Fevers) 04/2012
1	Bacterial Infections (Bacterial Infection) 04/2012
1	Lymphocytosis 04/2012

Drug/Important Bio-Agent (IBA)

13	Anti-Bacterial Agents (Antibiotics)IBA 07/2021 - 03/2002
9	GangliosidesIBA 09/2012 - 12/2004
8	Immunoglobulin G (IgG)IBA 02/2015 - 03/2008
8	AntibodiesIBA 02/2012 - 12/2004
6	Proteins (Proteins, Gene)FDA Link 05/2015 - 07/2005
6	AntigensIBA 02/2015 - 02/2011
5	Ketoconazole (Nizoral)FDA LinkGeneric 04/2011 - 04/2005
4	Mupirocin (Bactroban)FDA LinkGeneric 02/2020 - 01/2010
4	Virulence Factors (Pathogenicity Factors)IBA 02/2015 - 01/2002
4	OligosaccharidesIBA 07/2010 - 12/2004
3	Pharmaceutical PreparationsIBA 11/2021 - 12/2010
3	Methicillin (Metin)FDA Link 01/2021 - 01/2012
3	Colistin (Coly-Mycin)FDA Link 01/2020 - 01/2018
3	Vancomycin FDA LinkGeneric 01/2020 - 03/2005
3	CoagulaseIBA 01/2020 - 09/2003
3	Biomarkers (Surrogate Marker)IBA 12/2019 - 09/2010
3	Enterotoxins (Enterotoxin)IBA 03/2009 - 03/2002
3	Itraconazole (Sporanox)FDA LinkGeneric 07/2007 - 04/2005
3	DNA (Deoxyribonucleic Acid)IBA 12/2003 - 03/2002
2	Tigecycline (Tygacil)FDA Link 01/2021 - 01/2020
2	Daptomycin FDA Link 01/2021 - 01/2020
2	Linezolid (Zyvox)FDA Link 01/2021 - 01/2020
2	CytokinesIBA 12/2019 - 05/2015
2	ChlorhexidineIBA 01/2016 - 01/2010
2	SuperantigensIBA 02/2015 - 07/2005
2	ExfoliatinsIBA 02/2015 - 07/2003
2	Peptide Hydrolases (Proteases)FDA Link 01/2013 - 01/2012
2	Immunoglobulin A (IgA)IBA 01/2013 - 03/2009
2	ProcalcitoninIBA 04/2012 - 09/2010
2	NeopterinIBA 04/2012 - 09/2010
2	VaccinesIBA 02/2012 - 12/2011
2	Panton-Valentine leukocidinIBA 01/2010 - 07/2003
2	Genetic Markers (Genetic Marker)IBA 10/2009 - 07/2003
1	Fusidic Acid (Fucithalmic)IBA 01/2021
1	Ceftaroline FDA Link 12/2020
1	Staphylococcal enterotoxin AIBA 01/2020
1	quinupristin-dalfopristin (Synercid)FDA Link 01/2020
1	Biological ProductsIBA 01/2020
1	Carbapenems (Carbapenem Antibiotics)IBA 01/2020
1	Interleukin-10 (Interleukin 10)IBA 12/2019
1	Interleukin-12 (IL 12)IBA 12/2019
1	Interleukin-17 (Interleukin 17)IBA 12/2019
1	Interleukin-6 (Interleukin 6)IBA 12/2019
1	Interleukin-22 (IL-22)IBA 12/2019
1	Interleukin-18 (Interleukin 18)IBA 12/2019
1	QuinolonesIBA 09/2019
1	MacrolidesIBA 09/2019
1	AgarIBA 01/2019
1	Third Generation CephalosporinsIBA 01/2019
1	FluoroquinolonesIBA 01/2019
1	Ointments (Pastes)IBA 01/2017
1	Peptide Elongation Factor Tu (EF-Tu)IBA 05/2015
1	ChemokinesIBA 05/2015
1	Cysteine SynthaseIBA 05/2015
1	Hydroxymethyl and Formyl TransferasesIBA 05/2015
1	Protein Isoforms (Isoforms)IBA 05/2015
1	AcetyltransferasesIBA 05/2015
1	Histidine KinaseIBA 05/2015
1	Interferon-gamma (Interferon, gamma)IBA 05/2015
1	Phosphoglycerate Kinase (Kinase, Phosphoglycerate)IBA 05/2015
1	staphylococcal enterotoxin CIBA 02/2015
1	Complement Inactivating AgentsIBA 02/2015
1	Local Anti-Infective Agents (Antiseptics)IBA 10/2014
1	Attenuated VaccinesIBA 06/2012
1	Surface Antigens (Surface Antigen)IBA 06/2012
1	Membrane Proteins (Integral Membrane Proteins)IBA 06/2012

Therapy/Procedure

8	Therapeutics 07/2021 - 04/2007
2	Critical Care (Surgical Intensive Care) 02/2020 - 02/2004
1	Lung Transplantation 01/2021
1	Electronic Nose 03/2013